LDL Particle Number (LDL-P)

Metabolic

Lipid Metabolism

LDL particle number (LDL-P) counts the actual number of LDL particles in the blood, rather than the amount of cholesterol they carry. This distinction matters because small, dense particles carry less cholesterol but the same atherogenic risk, so particle count can be more predictive than standard LDL cholesterol. A longevity practice measures LDL-P to assess true atherogenic particle burden.

What It Measures

Actual count of LDL particles; more predictive than LDL-C (cholesterol concentration) because small dense particles carry less cholesterol but same atherogenic risk

Optimal vs. Lab Range

Longevity Optimal

<700 nmol/L

Target range for optimal health and longevity based on research.

Standard Lab

<1,000 nmol/L

Population-based reference range from standard labs.

Why It Matters

It is the number of LDL particles entering the artery wall, not the cholesterol inside them, that drives atherosclerosis, which is why high LDL-P can confer risk even when LDL-C looks normal, a situation called discordance. Identifying that discordance is a key longevity insight, because it uncovers cardiovascular risk that a conventional lipid panel would miss. A high particle count reflects more opportunities for particles to penetrate and inflame the vessel wall over a lifetime. LDL-P is interpreted alongside ApoB, LDL-C, sdLDL, triglycerides, and HOMA-IR. Lower values are generally favorable.

When Low

Generally favorable when low

When High

Atherosclerosis risk (even with normal LDL-C, high LDL-P confers risk — "discordance")

How to Optimize

Because particle number is closely tied to metabolic health, optimizing insulin sensitivity and reducing dietary carbohydrate load can lower LDL-P, often more than they change LDL-C. Broader metabolic optimization through diet and exercise supports this. When particle burden stays high, statin therapy and, in selected cases, PCSK9 inhibitors are physician-directed options for lowering it. Retesting confirms whether the particle count, not just cholesterol, is improving. Targets and treatment are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Strong evidence

Key Interventions

Statin (clinical)

PCSK9

metabolic optimization

low-carb diet

Linked Compounds & Supplements

Berberine

Omega-3

Plant sterols

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Annual

Reporting unit

Confirm with the performing lab — units vary by region.

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift LDL Particle Number (LDL-P).
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.